<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180150</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-A3334-II-01a</org_study_id>
    <nct_id>NCT04180150</nct_id>
  </id_info>
  <brief_title>A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Phase IIa Study of TQ-A3334 Combined With Entecavir in the Treatment of Untreated or HBV DNA Negative Subjects With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded, placebo-controlled, phase IIa study to evaluate safety
      and efficacy of TQ-A3334 combined with entecavir in the untreated or HBV DNA negative
      subjects with Chronic Hepatitis B.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.</time_frame>
    <description>Cmax is the maximum plasma concentration of TQ-A3334 or metabolite(s).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.</time_frame>
    <description>To characterize the pharmacokinetics of TQ-A3334 by assessment of time to reach maximum plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.</time_frame>
    <description>To characterize the pharmacokinetics of TQB3804 by assessment of area under the plasma concentration time curve from zero to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine</measure>
    <time_frame>Hour 0, 1.5 , 12 , 24 , 72 hours post-dose at week 1 and week 12; Hour 0 at week 7.</time_frame>
    <description>Including IFN-α, IFN-γ, TNF-α, IL-6, IL-2, MCP-1 and so on.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV biomarker</measure>
    <time_frame>Day 1 pre-dose, day 84, day 168, day 336 post-dose.</time_frame>
    <description>Including HBsAg, HBsAb, HBeAb, anti-HBc, HBV-DNA, HBV RNA and HBcrAg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte function</measure>
    <time_frame>Hour 0 pre-dose, day 56, day 84, day 168 at post-dose.</time_frame>
    <description>Analysis of immune cell response to hepatitis B antigen after treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>TQ-A3334 combined with entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive TQ-A3334 (1.2 mg QW) and entecavir (0.5 mg qd) in 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo combined with entecavir</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive placebo (0 mg QW) and entecavir (0.5 mg qd) in 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-A3334</intervention_name>
    <description>TQ-A3334 is a kind of TLR7 receptor agonist.</description>
    <arm_group_label>TQ-A3334 combined with entecavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is a treatment which is designed to have no therapeutic value.</description>
    <arm_group_label>Placebo combined with entecavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir Tablet</intervention_name>
    <description>Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.</description>
    <arm_group_label>Placebo combined with entecavir</arm_group_label>
    <arm_group_label>TQ-A3334 combined with entecavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. 18 and 65 years old ; 2. HBsAg positive at least for 6 months ; 3. HBeAg positive
             chronic hepatitis B, HBV DNA &gt; 10^5 copies/ml; 4. Fibroscan ≤ 12.4 Kpa，2×ULN ≤ ALT ≤
             ULN; 5. New diagnosed chronic hepatitis B subjects;

        Exclusion Criteria:

          -  1.Combined with other virus infection ; 2.Has cirrhosis or hepatocellular carcinoma;
             3.Has autoimmune diseases; 4.Has thyroid disease; 5.Has eye diseases; 6.Has clinically
             significant abnormalities/diseases ≥ grade 2; 7.Has history of chronic kidney disease,
             renal insufficiency, renal anemia; 8.Peripheral blood index is low; 9.Has a history of
             allergy to experimental drugs or their excipients; 10.Has participated in other
             clinical trials within 3 months; 11.Breastfeeding or pregnant women.; Men unwilling to
             use adequate contraceptive measures during the study; 12.According to the judgement of
             the researchers, there are other factors that subjects are not suitable for the
             study.; 13.Has history of drug abuse in the past five years;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Junqi Niu, M.D.</last_name>
    <phone>0431-88782168</phone>
    <email>junqiniu@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong Ren, M.D.</last_name>
    <phone>023-63693213</phone>
    <email>renhong0531@vip.sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The second affiliated hospital of chongqing medical university</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Ren, M.D.</last_name>
      <phone>023-63693213</phone>
      <email>renhong0531@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Hong Ren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jinlin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junqi Niu, M.D.</last_name>
      <phone>0431-88782168</phone>
      <email>junqiniu@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Junqi Niu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

